JP2004531538A5 - - Google Patents

Download PDF

Info

Publication number
JP2004531538A5
JP2004531538A5 JP2002584920A JP2002584920A JP2004531538A5 JP 2004531538 A5 JP2004531538 A5 JP 2004531538A5 JP 2002584920 A JP2002584920 A JP 2002584920A JP 2002584920 A JP2002584920 A JP 2002584920A JP 2004531538 A5 JP2004531538 A5 JP 2004531538A5
Authority
JP
Japan
Prior art keywords
methyl
group
hydrogen
ethyl group
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002584920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531538A (ja
Filing date
Publication date
Priority claimed from FR0105843A external-priority patent/FR2823975B1/fr
Application filed filed Critical
Publication of JP2004531538A publication Critical patent/JP2004531538A/ja
Publication of JP2004531538A5 publication Critical patent/JP2004531538A5/ja
Pending legal-status Critical Current

Links

JP2002584920A 2001-04-27 2002-04-26 ピリドインドロン誘導体に基づく医薬組成物および抗癌剤 Pending JP2004531538A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone
PCT/FR2002/001450 WO2002087575A1 (fr) 2001-04-27 2002-04-26 Associations pharmaceutiques a base de derives de pyridoindolone et d'agents anticancereux

Publications (2)

Publication Number Publication Date
JP2004531538A JP2004531538A (ja) 2004-10-14
JP2004531538A5 true JP2004531538A5 (enExample) 2005-12-22

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002584919A Pending JP2004528343A (ja) 2001-04-27 2002-04-26 抗癌薬の製造のためのピリドインドロン誘導体の使用
JP2002584920A Pending JP2004531538A (ja) 2001-04-27 2002-04-26 ピリドインドロン誘導体に基づく医薬組成物および抗癌剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002584919A Pending JP2004528343A (ja) 2001-04-27 2002-04-26 抗癌薬の製造のためのピリドインドロン誘導体の使用

Country Status (33)

Country Link
US (3) US7524857B2 (enExample)
EP (2) EP1385513B1 (enExample)
JP (2) JP2004528343A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1505511A (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE314070T1 (enExample)
BG (2) BG108260A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2443012C (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ299465B6 (enExample)
DE (2) DE60208365T2 (enExample)
DK (2) DK1385512T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2254683T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400744A2 (enExample)
IL (4) IL158312A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034787L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385513E (enExample)
RS (2) RS50790B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087574A2 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
EP0755454B1 (en) * 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Similar Documents

Publication Publication Date Title
JP2004516314A5 (enExample)
JP2006182786A5 (enExample)
JP2010513448A5 (enExample)
JP2008502696A5 (enExample)
JP2008514732A5 (enExample)
JP2008523126A5 (enExample)
JP2008514611A5 (enExample)
JP2008525417A5 (enExample)
JP2009523777A5 (enExample)
JP2004532209A5 (enExample)
RU2006108799A (ru) N3-замещенные имидазопиридиновые ингибиторы c-kit
LU92155I2 (fr) Crizotinib, éventuellement sous la forme d'un sel,hydrate ou solvate pharmeceutiquement acceptable
JP2005538100A5 (enExample)
JP2019511489A5 (enExample)
JP2005511547A5 (enExample)
JP2005518357A5 (enExample)
JP2008534453A5 (enExample)
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
JP2006510606A5 (enExample)
PL378201A1 (pl) Sposób farmaceutyczny oraz związki wytwarzane tym sposobem
JP2004521150A5 (enExample)
JP2005533052A5 (enExample)
JP2003512327A5 (enExample)
JP2010518158A5 (enExample)
JP2009501745A5 (enExample)